29.8 C
New York
Tuesday, June 25, 2024

Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients

Moderna and Merck’s Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free …

This post was originally published on this site

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,024FansLike
396,312FollowersFollow
2,300SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x